Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 February 2022 | Story Lacea Loader

On the morning of 23 February 2022, some of the entrance gates to the Bloemfontein Campus were blocked by groups of protesting students. The gates were cleared by members of Protection Services and traffic could continue to enter and exit the campus.

Sporadic disruption of classes occurred during the course of the day, with several students being arrested by the South African Police Service (SAPS) for disruption of classes, which is contravention of the interdict.

The disruptive behaviour stems from students’ unhappiness with the response to the memorandum handed to the university management by the Bloemfontein Campus Central Student Representative Council (CSRC) on 21 February 2022. Also on 21 February, a memorandum was handed to the management of the Qwaqwa Campus by the campus’ CSRC. The Qwaqwa Campus was temporarily closed yesterday, following violent protest action this week; the date for the reopening of the campus will be communicated in due course. 

Today’s disruptive behaviour demonstrated by the group of students on the Bloemfontein Campus is condemned and will not be tolerated.

During this week and on numerous occasions before that, the university management has been in extensive engagements with the CSRCs on both campuses; concessions were made where possible, as was demanded in the two memoranda. However, the responses given, and the concessions made by the university were not accepted by the student leadership of the Bloemfontein Campus CSCR in particular, with more demands being made.


Concessions from the beginning of 2022:

To ensure that students register successfully for the 2022 academic year, the UFS has granted a number of financial concessions to students since the beginning of the year. The financial support given was specifically intended to fast-track the registration process of students with outstanding debt, and those awaiting confirmation of funding from the National Student Financial Aid Scheme (NSFAS). 

These concessions included:

  • Allowing students who have previously registered for foundation programmes and those who have continued with mainstream programmes to register without the prerequisite of a first payment. The provision was granted to students who applied with the N+ rule and whose respective foundation programmes are included in the Department of Higher Education and Training-funded list.
  • Permitting students with outstanding debt of up to R25 000 and who await NSFAS funding to register provisionally.
  • The university also allowed conditional registration for first-time entering students, giving those who have applied for NSFAS funding until 28 February 2022 to finalise their registration. First-time entering students, both residential and non-residential, could register conditionally, provided that they pay an amount of R500.

Demands in the two memoranda received from the CSRCs on the Bloemfontein and Qwaqwa Campuses included matters such as private accommodation; emergency accommodation; catch-up plans for students who have not yet registered; a registration threshold increase to R30 000; NSFAS allowances; and the extension of registration for international students without study permits. The Bloemfontein Campus CSRC did not accept the university’s responses to the memorandum.

The university management will continue engaging with the SRC.

Safety measures in place:

The situation on the Bloemfontein Campus is closely monitored. Protection Services is on high alert and continues to work closely with the SAPS to ensure stability on the campus.

 

Issued by:
Lacea Loader
Director: Communication and Marketing
University of the Free State
loaderl@ufs.ac.za

23 February 2022

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept